AxoGen (AXGN) Tops Q2 EPS by 9c; Reaffirms FY22 Guidance

AxoGen (NASDAQ: AXGN) reported Q2 EPS of ($0.06), $0.09 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $34.5 million versus the consensus estimate of $33.82 million.

GUIDANCE:

AxoGen sees FY2022 revenue of $135-142 million, versus the consensus of $139.3 million.

For earnings history and earnings-related data on AxoGen (AXGN) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Wintermar acquires full control of Fast Offshore Supply, adding 5 new CTVs
• Goldman reinstates Estee Lauder rating, sees turnaround driving growth and margins